Cerylid claims 95 per cent success rate in early screening
29 July, 2002 by Tanya HollisGenomics-based drug discovery company Cerylid Biosciences has announced that its lead anti-cancer compound successfully halted the disease in 95 per cent of human cell lines used.
Eiffel gains control of R&D arm
29 July, 2002 by Tanya HollisEiffel Technologies has gained full control of its research and development arm in a move that will ensure all future revenue streams flow directly to the drug reformulation company.
Market over-reacting to cochlear fears: analysts
29 July, 2002 by Tanya HollisA warning on meningitis risk by US cochlear implant manufacturer Advanced Bionics and the Food and Drug Administration last week took its toll on market leader Cochlear.
Mass spectrometry: Critical mass
26 July, 2002 by Melissa TrudingerDuring the past decade, dramatic progress in the field of mass spectrometry has resulted in a large increase in the number of commercially available mass spectrometry (MS) instruments principally used for biochemical analysis. Advances in mass spectrometry instrumentation, driven primarily by proteomics and the need to identify low abundance proteins (<50 femtomoles) has resulted in the current generation of instruments having approximately 50 times more sensitivity combined with substantially greater resolution than mass spectrometers available only four or five years ago.
Vision Bio chief spells out strategy
26 July, 2002 by Melissa TrudingerVision BioSystems' recent acquisition of British reagent company Novocastra Laboratories is part of a broader strategy to expand into the global diagnostic instruments market, according to managing director Michael Ohanessian.
Genera names new CEO
26 July, 2002 by Tanya HollisWalter and Eliza Hall Institute spin-out Genera Biosystems has appointed a new chief executive officer to spearhead partnership opportunities in the United States.
New report puts Victoria on top
25 July, 2002 by Tanya HollisVictoria has cemented its reputation as Australia's biotechnology and bioscience industry leader, which was initiated with the introduction of the smallpox vaccine 80 years ago, a report has found.
Plasvacc heads for the fast-track
25 July, 2002 by Pete YoungOne of the rare biotech companies with origins in rural Australia, Plasvacc Pty Ltd, is dropping its low-key strategy and moving into fast-track expansion mode.
Flinders teams with pharma Elan in Parkinson's research
25 July, 2002 by Melissa TrudingerA research team at Flinders University in South Australia is collaborating with biopharmaceutical company Elan Pharmaceuticals on a project investigating Parkinson's disease.
Vic biotech projects net $60m in second-round grants
25 July, 2002 by Tanya HollisVictoria's government unveiled its second round of Science, Technology and Innovation Grants today, with almost $60 million being poured into mostly biotechnology projects.
Grain Biotech walks with the giants in international tech awards
25 July, 2002 by Melissa TrudingerAn Australian agbiotech company has been named as a finalist in this year's World Technology Awards for its excellence in wheat transformation.
AusBiotech to wave the flag for pre-clinical industry
24 July, 2002 by Tanya HollisIndustry organisation AusBiotech is to set up a working group to deliver the recommendations of a pre-clinical development meeting held in Melbourne this week.
CSIRO scientists isolate semi-dwarfing rice gene
24 July, 2002 by Melissa TrudingerResearchers at CSIRO Plant Industry have used the publicly available rice genome sequence to isolate the semi-dwarfing gene in varieties responsible for the 'green revolution' and develop 'perfect' markers for it.
BresaGen parts company with British Biotech
24 July, 2002 by Tanya HollisAdelaide-based company BresaGen and British Biotech have ended a collaboration to develop GM-CSF antagonist E21R, after fresh tests failed to confirm previous assessments of its commercial prospects.
Processed coral may be used in bone grafts
23 July, 2002 by Melissa TrudingerA group based at the University of Technology, Sydney, has developed a unique method of processing coral, which may allow it to be used in orthopaedic implants.
